Related Experiment Video
Updated: Feb 15, 2026

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
Published on: August 17, 2022
The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats
Ender Hur1, Devrim Bozkurt, Ozge Timur
1Department of Nephrology, Ege University, Izmir, Turkey. hurender@hotmail.com
Introduction:
Encapsulated peritoneal sclerosis (EPS) is a devastating complication of peritoneal dialysis. We aimed to investigate the effects of mycophenolate mofetil (MMF) treatment in experimental EPS in rats.
Methods:
40 nonuremic Wistar albino rats were divided equally into 4 groups: control rats received 2 ml isotonic saline intraperitoneally daily for 3 weeks without any other treatment. The chlorhexidine gluconate group received intraperitoneally 2 ml/200 g injection of chlorhexidine gluconate and ethanol dissolved in saline for 3 weeks. The resting group received chlorhexidine gluconate (0 - 3rd week) + peritoneal resting (4th - 6th week). The MMF group received chlorhexidine gluconate (0 - 3rd week) + 125 mg/l MMF in drinking water (4th - 6th week). Dialysate cytokine levels, leukocyte count, peritoneal thickness, inflammation and fibroblast activities were evaluated.
Results:
Although the MMF and resting groups showed beneficial effects on ultrafiltration and D1/D0 glucose compared to the chlorhexidine gluconate group, only MMF treatment improved dialysate TGFβ1, VEGF and MCP-1 levels compared to the resting group. Inflammatory activity and vascularity observed in a tissue biopsy, including capillaries number per mm2 of submesothelial area, decreased in the treatment group.
Conclusions:
MMF treatment has beneficial effects on EPS via inhibiting inflammation and neovascularisation by reducing dialysate VEGF overexpression.
Insights
Mycophenolate mofetil (MMF) treatment effectively reduced inflammation and neovascularization in experimental encapsulated peritoneal sclerosis (EPS) in rats. MMF therapy improved key markers, offering a potential therapeutic strategy for this dialysis complication.
Area of Science:
- Nephrology
- Gastroenterology
- Immunology
Background:
- Encapsulated peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis.
- Current treatment options for EPS are limited, necessitating research into novel therapeutic agents.
Purpose of the Study:
- To investigate the efficacy of mycophenolate mofetil (MMF) in an experimental rat model of EPS.
- To evaluate the impact of MMF on inflammatory and fibrotic markers in EPS.
Main Methods:
- Rats were induced with EPS using chlorhexidine gluconate and ethanol.
- Treatment groups included control, chlorhexidine gluconate alone, peritoneal rest, and MMF administration.
- Key parameters assessed included dialysate cytokine levels, leukocyte counts, and peritoneal tissue histology.
Main Results:
- MMF treatment and peritoneal rest improved ultrafiltration and glucose transport compared to the control group.
- MMF significantly reduced dialysate levels of TGFβ1, VEGF, and MCP-1 compared to the resting group.
- Histological analysis showed decreased inflammation and vascularity in the MMF-treated group.
Conclusions:
- MMF demonstrates beneficial effects in experimental EPS by inhibiting inflammation and neovascularization.
- Reduced dialysate VEGF overexpression is a key mechanism by which MMF exerts its therapeutic effects.
- MMF represents a promising therapeutic candidate for managing encapsulated peritoneal sclerosis.
More Related Videos
Related Concept Videos
Peritoneal Dialysis III: Nursing Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Biological Effects of Radiation

